Bomaitech Aims for ChiNext IPO with RMB 1.7 Billion Fundraising Target

Smart Medical Device Network News: Recently, the official website of the Shenzhen Stock Exchange showed,BrosMed Medical Co., Ltd.(Abbreviation:BrosMed Medical) The application for public offering of shares and listing on the ChiNext has been accepted.

BrosMed Medical, as a leading enterprise in the field of vascular interventional medical devices, occupies a leading position in the market with its technical advantages and scaled production capacity in products such as balloon catheters.

According to Frost & Sullivan data, in 2024 BrosMed Medical ranked fourth in the Chinese Coronary Balloon Dilation Catheter market with a 9.6% market share, and ranked first among domestically produced brands; it also ranked fifth in the Chinese Peripheral Artery Balloon Dilation Catheter market with a 4.7% market share.

2013By the end of the year2014At the beginning of the yearAThe round of financing laid the foundation for early-stage R&D,2015YearBRound of financing boosts product pipeline expansion,2020During the pandemic in 2020, it was completed in just4Million yuan in just a few monthsCRound of financing (led by Hillhouse Ventures), demonstrating the market's firm recognition of its technical value.2025Year6MonthDIn the round of financing,IDGTop-tier institutions such as capital jointly entered the market, and submitted after half a year.IPOApplication, capital boost effect is significant.

From 2022 to 2024 and the first half of 2025, BrosMed Medical achieved revenues of 207 million yuan, 335 million yuan, 460 million yuan, and 303 million yuan, respectively; net profits attributable to parent company were -30.2642 million yuan, 28.5025 million yuan, 77.4426 million yuan, and 35.8016 million yuan, respectively.

Backed by star capital such as Tencent, BrosMed Medical's journey to the ChiNext Board represents a microcosm of China's high-end medical device industry leveraging the capital market for upgrading. In the future, if BrosMed Medical can effectively convert its fundraising efficiency, continuously strengthen its core technology barriers, balance the pace of domestic substitution and global expansion, and properly address industry competition and policy changes, it is expected to become a leading player in China's medical device sector.“Go Global”The benchmark enterprise.

Editor's Express

1

Enterprise interviews, in-depth reporting and promotion of products and technologies, industry report consulting, contributions;

2

Contact: 13714842321 (Same on WeChat)